Bionomics, the Australian pharmaceutical firm, will conduct the Phase II trials, for the novel drug against mesothelioma cancer, in the first months of the year 2010. First trial will start with six patients suffering from mesothelioma cancer.
One of the doctors involved in this project said that the premise of this trial is to test how BCN 105 can improve the lifespan of patients diagnosed with mesothelioma cancer, this aggressive type of cancer. Bionomics Chief Executer Officer, Deborah Rathjen said that this is a very important step for mesothelioma treatment and can bring important and vital information about the perimeters of the disease.
Mesothelioma in Australia
Mesotheliona is known as a rare type of cancer caused by exposure to asbestos fibers, and it is also known that this type of cancer is deadly. People suffering from this cancer, if not diagnosed in time, even after following the mesothelioma treatment, they can die in less then two years.
Bionomics also revealed information regarding the large number of mesothelioma cancer patients in Australia, as almost six hundred of new mesothelioma cancer cases are diagnosed every year. Mesothelioma cancer is a very complicated disease and it is very hard to beat.
Great Expectations
Deborah Rathjen, mesothelioma doctor, is talking about their expectation regarding the newest drug BCN105, as they are hoping to work just as they have planned. “With many chemotherapies and radiation therapies, malignant cells can develop immunity or resistance to the medication.” Dr. Rathjen said and she also believes that after using the BCN105, malignant cells will be stopped from growing into malignant tumors.
A drug that can stop malignant cell from growing up in to the organism and form malignant tumors to be found is very important. The team at the Bionomics believes in the new drug BCN105 and they are very optimistic concerning the results for Phase II of the mesothelioma trials. If BCN 105 will have success the firm will consider the commercial application for the mesothelioma drugs.